Phase II study of induction therapy: S-1 and cisplatin with concurrent radiation for patient with stage IIA-IIIA locally advanced non-small cell lung cancer.

Phase II study of induction therapy: S-1 and cisplatin with concurrent radiation for patient with stage IIA-IIIA locally advanced non-small cell lung cancer. - Induction therapy of S-1 and cisplatin with concurrent radiation for NSCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008205

Enrollment

Registered

2012-06-19

Start date

2011-07-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

cisplatin plus TS-1 combination induction chemoradiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Provided written informed consent 2)NSCLC with histologic proof(without LCNEC) 3)Resectable pathological stage IIA to IIIB NSCLC (proved by E-BUS/TBMA or mediastinoscopy for lymph node metastasis) 4)More than age 20 years old 5)No previous treatment 6)No double cancer 7)Sufficient oral intake 8)Performance status (PS) 0 or 1 9)Normal ECG 10)Patients also had to have adequate organ function

Exclusion criteria

Exclusion criteria: 1)Stage II without lymph node metastasis, stage IIIA with single N2, and stage IIIB with N3beta or gamma 2)Patients with a history of drug hypersensitivity 3)Patients with administration of phenitoin or potassiun warfarin 4)Patients with administration of flucytosine 5)Active infection 6)Active ulcer in digestive tract 7)Serious nonsurgical complications 8)Diarreha 9)Pregnant

Design outcomes

Primary

Measure	Time frame
Completion rate for the schedule	—

Secondary

Measure	Time frame
Safety, 3-yr and 5-yr survival rate,3-yr and 5-yr relapse free survival rate.	—

Countries

Japan

Contacts

Public ContactTomoshi Tsuchiya

Nagasaki Graduate School of Biomedical Sciences Division of Surgical Oncology

tomoshi@nagasaki-u.ac.jp095-819-7304

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026